Head-to-head · WeighScore
Boston Medical Group vs Shapely
The verdict
Shapely takes it — 65.4/100 to 61.9/100.
Shapely grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Shapely is a GLP-1 telehealth platform founded by Dr.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Boston Medical Group | Shapely |
|---|---|---|
| WeighScore | 61.9/100 | 65.4/100 |
| Grade | C | C |
| Scorecard rank | #279 | #220 |
| Semaglutide | $199/mo (starting strength, rising with dose, compounded) | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | 7 states | 4 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #279 · C
Strengths
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
Where it loses points
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
- The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
- Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #220 · C
Strengths
- Founded by Dr. Justin Zaghi, MD/MBA — Harvard-trained, board-certified in internal medicine and obesity medicine, with Medical Director Ana Lisa
- Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) covered by major PPO and Medicare at copay
- Compounded semaglutide from $99/month with free 2-day shipping, syringes, and supplies included via 503A/503B pharmacy
- 1:1 registered dietitian (RDN) and monthly video provider visits included in every plan; unlimited chat and app support
- Cellular smart scale provided to qualifying patients for ongoing weight tracking throughout the program
Where it loses points
- Currently available only in California, Florida, New York, and Texas — 46 states unserved despite announced expansion
- Telehealth subscription ($99/mo self-pay, $49 first-month promo) is charged separately from compounded medication cost
- Labs not included — $75 flat rate for uninsured patients; baseline bloodwork may be required before prescribing
- No LegitScript certification found on any public page
- Compounding pharmacy partner not named publicly; 503A/503B status claimed but specific pharmacy undisclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.